
European Journal of Medicinal Chemistry (2021)
Update date:2022-07-30
Topics:
Kraj?ovi?ová, Soňa
Jorda, Radek
Vanda, David
Soural, Miroslav
Kry?tof, Vladimír
Herein, we report an efficient synthetic approach towards trisubstituted imidazo [4,5-c]pyridines designed as inhibitors of Bruton's tyrosine kinase (BTK). Two alternative synthetic routes for the simple preparation of desired compounds with variable substitutions at the N1, C4, C6 positions were introduced with readily available building blocks. Further, the developed synthetic approach was feasible for isomeric compounds bearing imidazo [4,5-b]pyridine scaffolds. In contrast to expectations based on previous studies, the imidazo [4,5-c]pyridine inhibitor exhibited a significantly higher activity against BTK compared to its imidazo [4,5-b]pyridine isomer. An inherent SAR study in the series of imidazo [4,5-c]pyridine compounds revealed a remarkably high tolerance of C6 substitutions for both hydrophobic and hydrophilic substituents. Preliminary cellular experiments indicated selective BTK targeting in Burkitt lymphoma and mantle cell lymphoma cell lines. The inhibitors could thus serve as starting points for further development, eventually leading to BTK inhibitors that could be used after ibrutinib failure.
Contact:86-510-82853889
Address:Rm.3732, No.18-2,Yonghe Rd.,Wuxi,Jiangsu,214023,China
Nanjing distinctions Medical Technology Co., Ltd.(expird)
Contact:+86-15996203785 13914714059
Address:nanjing,jiangsu , China
Contact:0091-265-2313036
Address:311, ATLANTIS HEIGHTS SARABHAI MAIN ROAD,VADIWADI ,VADODARA
Contact:86-574-26865651
Address:529 YuanBaoShan Road, Beilun District
JIANGXI AIFEIMU TECHNOLOGY CO.,LTD
Contact:+86-570-6040289
Address:FINECHEMICAL PARK,ZIBU TOWN,WANNIAN COUNTY,JIANGXI PROV.,CHINA,ZIP
Doi:10.1016/j.tetlet.2009.02.011
(2009)Doi:10.1021/acs.jafc.9b05507
(2019)Doi:10.1002/chem.201503123
(2015)Doi:10.1055/s-0030-1260199
(2011)Doi:10.1039/P19870002411
(1987)Doi:10.1039/b819959k
(2009)